U.S. jury fails to reach verdict in latest J&J talc trial
NEW YORK (Reuters) – A South Carolina jury on Friday could not agree on a verdict in a case of a woman whose family said her long-term use of Johnson…
U.S. jury fails to reach verdict in latest J&J talc trial
NEW YORK (Reuters) – A South Carolina jury on Friday could not agree on a verdict in a case of a woman whose family said her long-term use of Johnson…
FDA approves BioMarin rare metabolic disorder drug, shares rise
(Reuters) – U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc’s Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending shares of the biotechnology company up 3 percent after hours.…
Ebola patients slip out of Congo hospital as medics try to control outbreak
MBANDAKA, Democratic Republic of Congo (Reuters) – Three patients infected with the Ebola virus slipped out of an isolation ward at a hospital in the Congolese city of Mbandaka, health…
Two more die of Ebola in Congo, seven new cases confirmed
MBANDAKA, Democratic Republic of Congo (Reuters) – Two more people have died from Ebola and seven new cases were confirmed in Democratic Republic of Congo, authorities said on Tuesday, but…
FDA issues warning letters to companies selling kratom products
(Reuters) – The U.S. Food and Drug Administration said on Tuesday it issued warning letters to three companies that illegally marketed and distributed products containing the substance, kratom, which they…
Congo begins giving experimental Ebola vaccine to medics
MBANDAKA, Democratic Republic of Congo (Reuters) – Congo began administering an experimental Ebola vaccine to medical staff in the northwestern city of Mbandaka on Monday to tackle an outbreak of…
Merck KGaA’s lung cancer drugs show promise in early-stage trials
FRANKFURT (Reuters) – Germany’s Merck KGaA said two of its experimental oncology drugs showed early signs of promise in certain lung cancer patients, potentially helping efforts to find drug-industry partners…
Evolus investors frown as FDA declines to approve Botox rival
(Reuters) – U.S. health regulators on Wednesday declined to approve Evolus Inc’s (EOLS.O) rival product to Allergan Plc’s (AGN.N) Botox, citing deficiencies related to the chemistry and manufacturing of its…
Evolus investors frown as FDA declines to approve Botox rival
(Reuters) – U.S. health regulators on Wednesday declined to approve Evolus Inc’s (EOLS.O) rival product to Allergan Plc’s (AGN.N) Botox, citing deficiencies related to the chemistry and manufacturing of its…